Trials / Terminated
TerminatedNCT05629364
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Kiora Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 21 Years
- Healthy volunteers
- Not accepted
Summary
A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, versus Vehicle Control in the treatment of Dry Eye Disease in Patients with Autoimmune Disease
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KIO-101 | Randomized, Controlled |
Timeline
- Start date
- 2023-03-15
- Primary completion
- 2024-01-09
- Completion
- 2024-01-09
- First posted
- 2022-11-29
- Last updated
- 2024-01-10
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT05629364. Inclusion in this directory is not an endorsement.